1249 related articles for article (PubMed ID: 19299742)
1. M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro.
Leidi M; Gotti E; Bologna L; Miranda E; Rimoldi M; Sica A; Roncalli M; Palumbo GA; Introna M; Golay J
J Immunol; 2009 Apr; 182(7):4415-22. PubMed ID: 19299742
[TBL] [Abstract][Full Text] [Related]
2. Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum.
Lefebvre ML; Krause SW; Salcedo M; Nardin A
J Immunother; 2006; 29(4):388-97. PubMed ID: 16799334
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the effects of IL-3, granulocyte-macrophage colony-stimulating factor, and macrophage colony-stimulating factor in supporting monocyte differentiation in culture. Analysis of macrophage antibody-dependent cellular cytotoxicity.
Young DA; Lowe LD; Clark SC
J Immunol; 1990 Jul; 145(2):607-15. PubMed ID: 2142182
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
[TBL] [Abstract][Full Text] [Related]
5. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2.
Golay J; Manganini M; Facchinetti V; Gramigna R; Broady R; Borleri G; Rambaldi A; Introna M
Haematologica; 2003 Sep; 88(9):1002-12. PubMed ID: 12969808
[TBL] [Abstract][Full Text] [Related]
6. Monocyte-mediated lysis of acute myeloid leukemia cells in the presence of the bispecific antibody 251 x 22 (anti-CD33 x anti-CD64).
Chen J; Zhou JH; Ball ED
Clin Cancer Res; 1995 Nov; 1(11):1319-25. PubMed ID: 9815927
[TBL] [Abstract][Full Text] [Related]
7. Systematic validation of specific phenotypic markers for in vitro polarized human macrophages.
Ambarus CA; Krausz S; van Eijk M; Hamann J; Radstake TR; Reedquist KA; Tak PP; Baeten DL
J Immunol Methods; 2012 Jan; 375(1-2):196-206. PubMed ID: 22075274
[TBL] [Abstract][Full Text] [Related]
8. Immunophenotypic characterisation of human peritoneal and alveolar macrophages and of human blood monocytes differentiated in the presence of either GM-CSF or M-CSF or a combination of GM-CSF/M-CSF.
Eischen A; Vincent F; Louis B; Schmitt-Goguel M; Bohbot A; Bergerat JP; Oberling F
Nouv Rev Fr Hematol (1978); 1992; 34(6):421-34. PubMed ID: 1300541
[TBL] [Abstract][Full Text] [Related]
9. Constitutive production of colony-stimulating factors by human hepatoma cell lines: possible correlation with cell differentiation.
Wang SY; Chen LY; Tsai TF; Su TS; Choo KB; Ho CK
Exp Hematol; 1996 Feb; 24(3):437-44. PubMed ID: 8599973
[TBL] [Abstract][Full Text] [Related]
10. Cytokine production by M-CSF- and GM-CSF-induced mouse bone marrow-derived macrophages upon coculturing with late apoptotic cells.
Yamazaki T; Nagata K; Kobayashi Y
Cell Immunol; 2008 Feb; 251(2):124-30. PubMed ID: 18511028
[TBL] [Abstract][Full Text] [Related]
11. Type I (CD64) and type II (CD32) Fc gamma receptor-mediated phagocytosis by human blood dendritic cells.
Fanger NA; Wardwell K; Shen L; Tedder TF; Guyre PM
J Immunol; 1996 Jul; 157(2):541-8. PubMed ID: 8752900
[TBL] [Abstract][Full Text] [Related]
12. Macrophage colony-stimulating factor enhances rituximab-dependent cellular cytotoxicity by monocytes.
Shimadoi S; Takami A; Kondo Y; Okumura H; Nakao S
Cancer Sci; 2007 Sep; 98(9):1368-72. PubMed ID: 17640305
[TBL] [Abstract][Full Text] [Related]
13. Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab.
Pander J; Heusinkveld M; van der Straaten T; Jordanova ES; Baak-Pablo R; Gelderblom H; Morreau H; van der Burg SH; Guchelaar HJ; van Hall T
Clin Cancer Res; 2011 Sep; 17(17):5668-73. PubMed ID: 21788356
[TBL] [Abstract][Full Text] [Related]
14. Muramyl dipeptide and mononuclear cell supernatant induce Langhans-type cells from human monocytes.
Mizuno K; Okamoto H; Horio T
J Leukoc Biol; 2001 Sep; 70(3):386-94. PubMed ID: 11527988
[TBL] [Abstract][Full Text] [Related]
15. Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and antiinflammatory stimuli.
Buechler C; Ritter M; Orsó E; Langmann T; Klucken J; Schmitz G
J Leukoc Biol; 2000 Jan; 67(1):97-103. PubMed ID: 10648003
[TBL] [Abstract][Full Text] [Related]
16. Role of colony-stimulating factor-1 in macrophage activation in tumor-bearing mice.
Sakata T; Iwagami S; Tsuruta Y; Teraoka H; Suzuki S; Suzuki R
J Immunol; 1992 Dec; 149(12):4002-8. PubMed ID: 1281198
[TBL] [Abstract][Full Text] [Related]
17. Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody.
Akewanlop C; Watanabe M; Singh B; Walker M; Kufe DW; Hayes DF
Cancer Res; 2001 May; 61(10):4061-5. PubMed ID: 11358826
[TBL] [Abstract][Full Text] [Related]
18. Antibody-mediated erythrolysis and erythrophagocytosis by human monocytes, macrophages and activated macrophages. Evidence for distinction between involvement of high-affinity and low-affinity receptors for IgG by using different erythroid target cells.
Rüegg SJ; Jungi TW
Immunology; 1988 Mar; 63(3):513-20. PubMed ID: 2965100
[TBL] [Abstract][Full Text] [Related]
19. Rituximab reduces the number of peripheral blood B-cells in vitro mainly by effector cell-mediated mechanisms.
Voso MT; Pantel G; Rutella S; Weis M; D'Alò F; Urbano R; Leone G; Haas R; Hohaus S
Haematologica; 2002 Sep; 87(9):918-25. PubMed ID: 12217803
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-10 contributes development of macrophage suppressor activities by macrophage colony-stimulating factor, but not by granulocyte-macrophage colony-stimulating factor.
Mochida-Nishimura K; Akagawa KS; Rich EA
Cell Immunol; 2001 Nov; 214(1):81-8. PubMed ID: 11902832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
